Investor Centre

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today provided an update on the company’s anti-fibrotic drug pipeline highlighting both the therapeutic areas of interest and competitive positioning of its LOXL2 and pan LOX inhibitors.

Speaking at the 2019 AusBiotech conference in Melbourne, Australia, Pharmaxis CEO Gary Phillips outlined the steps Pharmaxis has taken to develop a best in class status for its Lysyl oxidase like 2 (LOXL2) inhibitors and strong pre-clinical data in myelofibrosis for its pan-LOX inhibitor PXS-5505.

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced its US licensee Chiesi Group (Chiesi) has received detailed advice from the US Food and Drug Administration (FDA) on its plan to fulfil the requirements necessary to approve Bronchitol® (mannitol) for the treatment of adult cystic fibrosis patients in the United States. Based on this feedback Chiesi has added an additional month to its timetable. The FDA review of the Bronchitol NDA is therefore now expected to be completed in the second quarter of 2020.

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that following positive clinical Phase 1A study results, it has begun dosing healthy subjects in the second stage of its study of an oral anti-fibrotic Lysyl Oxidase (LOX) inhibitor. This drug is being targeted to treat cancers including myelofibrosis and pancreatic cancer.